Treatment

October 08, 2024

Perspectives on Treatment Developments for Psoriatic Disease

Over 20 years ago biologics were introduced for psoriasis and PsA. Since then even more targeted treatments have been introduced. Listen as dermatologist Dr. Steven Feldman from Wake Forest University School of Medicine, shares his perspectives on the latest treatments, resident memory T-Cells, and what’s to come (such as an oral IL-23 agent) with moderator Max Blitstein.

This episode is provided with support from Bristol Myers Squibb.

Your Guide to Biosimilars

Discover how FDA-approved biosimilars can help manage psoriatic disease.

Request Your Free Guide
Share
Related Items

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.